Obesity News

Medindia's Press Release’ section provides the latest press release on Obesity from across the world for the global audience. This page links to 508 Obesity press releases.

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

PR Newswire CRANBURY, N.J., April 17, 2025 CRANBURY, N.J., April 17, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...


Ypsomed and Sidekick Health launch a collaborative digital health solution for obesity management

PR Newswire NEW YORK, April 7, 2025 NEW YORK, April 7, 2025 /PRNewswire/ -- Ypsomed and Sidekick Health are launching an integrated digital health solution to better support people with obesity. Ypsomed's autoinjectors seamlessly integrate ...

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

PR Newswire CRANBURY, N.J., March 31, 2025 CRANBURY, N.J., March 31, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

Obesity Action Coalition Launches "Imagine a World Without Weight Stigma" Creative Contest Honoring 20th Anniversary

PR Newswire TAMPA, Fla., March 27, 2025 TAMPA, Fla., March 27, 2025 /PRNewswire/ -- To commemorate its 20th Anniversary in 2025, the Obesity Action Coalition (OAC) is excited to announce the launch of the "Imagine a World Without Weight ...

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

PR Newswire SAN DIEGO, March 26, 2025 13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: ...

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

PR Newswire CRANBURY, N.J., March 25, 2025 CRANBURY, N.J., March 25, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies

PR Newswire CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 12, 2025 - Élancé Therapeutics aims to improve current obesity treatment, specifically to increase overall body weight loss and fat mass loss, but preserve and even ...

Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity

PR Newswire BEIJING and BRIDGEWATER, N.J., March 10, 2025 BEIJING and BRIDGEWATER, N.J., March 10, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been ...

Ivím Health Raises Alarm as FDA Deadline Threatens Obesity Treatment Access

PR Newswire COLUMBUS, Ohio, March 4, 2025 COLUMBUS, Ohio, March 4, 2025 /PRNewswire/ -- In recognition of World Obesity Day, Ivim Health is proud to advocate on behalf of patients on their health journeys by providing personalized and ...

Obesity Care Week 2025 Challenges Everyone to "Commit to Care"

PR Newswire TAMPA, Fla., March 3, 2025 TAMPA, Fla., March 3, 2025 /PRNewswire/ -- Obesity Care Week (OCW) returns for its annual global campaign aimed at raising awareness, educating and advocating for individuals affected by obesity. This ...

Obesity News »

Why Do We Crave Unhealthy Food? Is the Brain to Blame?

Why Do We Crave Unhealthy Food? Is the Brain to Blame?

Understanding how brain chemistry and food decisions are linked to rising obesity and related health issues.

Surge in Adolescent Overweight/Obesity in England

Surge in Adolescent Overweight/Obesity in England

Study finds a 50% rise in overweight and obesity among adolescents in England, increasing from 22% in 2008–2010 to 33% in 2021–2023.

Weight Loss Drugs Are Changing What We Eat and How We Buy

Weight Loss Drugs Are Changing What We Eat and How We Buy

The increasing use of GLP-1 medications for weight loss is leading to significant changes in food preferences, with users consuming less processed foods, soda, and certain meats.

Weight Loss Benefits Last, Even After Regaining Some Weight

Weight Loss Benefits Last, Even After Regaining Some Weight

Losing a lot of weight provides long-term health benefits, even if some weight is regained.

Active Childhood, Stronger Lungs: Childhood Obesity Raises COPD Risk!

Active Childhood, Stronger Lungs: Childhood Obesity Raises COPD Risk!

A new study links childhood overweight and obesity to higher COPD risk, stressing early weight management for lung health.

More Obesity News

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.